about
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studySubcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisShort course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial.Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.APLAR rheumatoid arthritis treatment recommendations.Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsTreatment recommendations for psoriatic arthritis.Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.Treatment goals for moderate to severe psoriasis: an Australian consensus.Updated guidelines for the management of axial disease in psoriatic arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceEvidence for treating rheumatoid arthritis to target: results of a systematic literature search update.Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.Advances in rheumatoid arthritis.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function finIdentification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).Remission in psoriatic arthritis-where are we now?Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.
P50
Q30463476-084418A8-C621-4EA6-8DA1-98DF69FA4CDEQ30768239-08AA067E-3153-4433-A559-CC37B527EADFQ30811550-4064E80F-4C88-4BC0-BA74-047CEC8DDCE6Q31034753-21983150-49AD-4622-9D3C-6469474714D2Q31158500-CE8F960F-8598-489C-A095-0231112AE32AQ33665468-B0D4E6CE-3F8A-45E2-B500-3CE489D5307DQ34107962-6240B8F2-CFB8-4684-801F-3536A495BFFBQ34503686-4B0DBDDD-C82F-48D8-B3EC-4A0C7413E1A1Q35096375-75B0F999-696C-4689-8359-365744123BB4Q35553490-24E41F64-DAB6-4028-A35E-63C68491CA67Q35554130-D2E439E5-B661-46B2-9B80-DF2C5EA0BC49Q35579450-49708224-5522-44F0-A185-AAF7B2DEB392Q35590496-79819541-02CC-45BB-92A1-DA7D9263D207Q35762912-3CE9F082-135F-4AF6-BEF8-72F5ACB5C7ECQ37085663-6618D20F-49E3-4DB2-97D1-2C65697AB8CFQ37284516-5246AA99-B3AC-4423-9A7A-F2D777ED15D8Q37504296-86478055-1187-4CCA-A735-E71B91866F66Q37612672-3D8EE723-9004-4B38-8513-AE8B2B2E5CD5Q37690888-E0D8AAA2-01B4-40F4-8ED2-A33C1A7D51CFQ38075023-61B5A2BA-B0DF-4946-A65C-6E566DC304BFQ38264282-AAD8C3A2-D2DE-4750-BCC8-B4AD972EF92BQ38476881-D2F337B1-605C-4A40-849F-4F44EECB2154Q38492012-579A4A7A-6882-4C5A-B8E1-4826FCE2BCA9Q38691418-FC765272-87CC-4578-82AC-5A07F734F16CQ39182272-B5EDC432-32E4-4F63-BE0E-CAD8A49B77D0Q40305889-C33D0056-4D81-445B-AA46-7EE500DB6700Q40656308-4CDFC583-B609-4105-B07C-38AD4AA42476Q40948833-51DFE1BC-4CBD-4DD8-98D3-CF2426989B04Q42598694-939516D9-325F-4252-8C8F-0F73BF04FAEFQ42683340-43A78E14-AEA0-4C64-BE87-9A521F3A58C3Q43730907-0DCF3279-C266-4292-9716-CF9CF766581AQ43795003-D561FA6C-E80B-482F-9477-6858B4205191Q44282751-D5E84963-CE1D-498C-8403-E173E18FF4D5Q44911715-B6A74D8D-15B5-42C6-B3F7-FDC92789C61FQ47108999-377DA6B5-7B87-4710-998E-78AC6D012E6BQ47381622-39044721-9495-4623-A91A-F8BA1676C9ABQ47432586-B2F3DB02-E8FA-46A8-848C-76C86A8DA40BQ49990438-3227DB99-0B62-496A-B953-AF17F5428916Q51171424-4CC6ABCA-8B37-458C-B877-03BD14CC919BQ51549470-5C06FA46-4240-4F10-A800-8621572EB681
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
P Nash
@ast
P Nash
@en
P Nash
@es
P Nash
@nl
type
label
P Nash
@ast
P Nash
@en
P Nash
@es
P Nash
@nl
prefLabel
P Nash
@ast
P Nash
@en
P Nash
@es
P Nash
@nl
P106
P31
P496
0000-0002-2571-788X